Novain 4 Mg/Ml Colírio, (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride blocks voltage‑gated sodium channels in peripheral nerve membranes of the corneal epithelium, preventing the initiation and propagation of nerve impulses. This reversible blockade stops the transmission of pain signals, producing rapid, short‑lasting anesthesia of the ocular surface.

The dosing regimen for Novain 4 Mg/Ml Colírio is determined by the prescribing clinician based on the specific procedure and patient needs. Typically, one to two drops are instilled in the affected eye shortly before the intended diagnostic or surgical intervention.

Safety data for Oxybuprocaine Hydrochloride in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Consequently, it should be used only if the potential benefit justifies any possible risk to the fetus or infant, and under medical guidance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Novain contains Oxybuprocaine Hydrochloride, an ester‑type local anesthetic, which provides rapid onset and short duration of action similar to other agents such as proparacaine or tetracaine. Compared with amide‑type anesthetics, ester agents may have a slightly higher risk of allergic reactions but are widely used for brief procedures due to their predictable profile.

Novain should be stored at ambient temperature, preferably below 25 °C, in its original container. Protect the bottle from direct sunlight, moisture, and extreme temperature fluctuations. Keep the product out of reach of children and discard any solution that appears discolored or contains particles.

The medication is supplied as sterile eye drops. The patient or clinician instills one to two drops onto the conjunctival sac of the target eye, typically a few minutes before the planned procedure. The eye should be gently closed for a brief period to allow even distribution of the anesthetic across the ocular surface.

Although rare, serious adverse events can include allergic reactions such as swelling, itching, or rash around the eye, corneal ulceration from prolonged exposure, and systemic anaphylaxis. Any signs of severe eye pain, vision loss, or systemic allergic response require immediate medical attention and discontinuation of the product.

Individuals with known hypersensitivity to Oxybuprocaine, other ester‑type local anesthetics, or any component of the formulation should avoid using Novain. It is also contraindicated in patients with active corneal infections, severe ocular surface disease, or when contact lenses are in place unless removed prior to administration.